Truist Securities Maintains Buy on Editas Medicine, Lowers Price Target to $12
Company Profile
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.